Biotech Startups

Vital Foams develops a field-deployable medical foam that conforms to complex wound geometries to deliver drugs uniformly, stop bleeding, prevent infection, and support faster healing. Applied through a handheld device, it is designed for military personnel and first responders providing emergency wound care in harsh environments.

1 investor

The BARDA Accelerator Network fosters health security innovation ecosystems worldwide and accelerates development and commercialization of next-generation health security solutions. It is established by the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services.

1 investor

Vitalief is a research operations partner that embeds experienced staff inside clinical research programs to run work across study start-up, financial and revenue cycle operations, workforce capacity, and portfolio delivery. It serves clinical research organizations and sponsors across the United States.

1 investor

A pharmaceutical company that develops and manufactures injectable medications across therapeutic areas including infectious disease, cardiology, anesthesia, gastroenterology, neurology, and oncology, as well as ophthalmic solutions and semi-solid products.

1 investor

Vitaliti is developing a therapeutic exercise mimetic intended to restore the ability to gain the benefits of exercise for people with cardiopulmonary disease. The company targets patients with debilitating cardiopulmonary conditions.

1 investor

Vitroprobe Analytics develops a patented biomolecular analysis method using Atom Probe Tomography to examine drug targets and their interactions at near-atomic resolution, helping pharmaceutical developers design and fine-tune new drugs. The company works in collaboration with academia and industry and originated from research at Chalmers University of Technology.

1 investor

VITRUVIAE is a biotechnology company developing cancer immunotherapies that target sugars and lipids found on tumor cells but not on healthy cells, aiming to improve tumor selectivity and counter drug resistance. Its dual sugar-lipid targeting platform is engineered into formats such as T-cell engagers, CAR immune cells, and radioactive delivery platforms, with a lead program (VTRU200) for acute myeloid leukemia.

1 investor

Viva In Vitro Diagnostics is a biotech company that researches and develops diagnostic solutions and services focused on the NLRP3 inflammasome and inflammatory processes, including biomarkers for early prognosis and patient stratification in sepsis. A spin-off of Murcia's biomedical research institute (IMIB), it serves hospitals, laboratories, and research centers, with its own lab in the Parque Científico de Murcia, Spain.

1 investor

Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.

1 investor

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases. The company operates research operations in Colorado and Austria.

1 investor

VivantX works in precision oncology, applying tumour molecular profiling and personalized therapeutics to cancer care. The company draws on advisors in medical and clinical oncology, data science, and digital health.

1 investor

Vivasure Medical develops polymer-based vascular closure devices and delivery systems for structural heart and endovascular interventions. The company operates an ISO 13485 certified manufacturing facility in Ireland and was acquired by Haemonetics Corporation in January 2026.

1 investor

VivoBio is a beneficial bacteria product developed for professional greenhouse and indoor growers, applied through irrigation, germination, or foliar spray to increase crop yield and shelf life. The company serves the agricultural sector with microbial solutions that support nutrient uptake, plant establishment, and crop quality.

1 investor

Vivorté develops and commercializes orthopedic medical devices focused on maintaining or improving bone strength and speeding the healing process for patients, surgeons, hospitals, and payers. It manufactures its products in cleanroom environments and processes biologic tissue under regulated quality standards.

1 investor

Vivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.

1 investor

VivoSens Medical develops medical solutions and products through an interdisciplinary team covering product design, development, sales, marketing, customer service, and supply chain. The company operates in the medical device sector.

1 investor

Vivtex is a drug development company applying computational science and pre-clinical research to advance new medicines. It operates in the biotech/therapeutics space, working on drug development and related laboratory research.

1 investor

VOC Diagnostics develops a diagnostic method that analyzes volatile organic compounds in blood plasma samples, combined with machine learning, to detect ovarian cancer at an early stage. The company is collecting clinical evidence toward regulatory approval in the European market, with a planned launch in 2029.

1 investor

Axia breeds and develops tomato and vegetable seeds using advanced techniques with emphasis on quality and respect for people, nature, and the environment. The company serves greenhouse growers worldwide with a focus on superior seed genetics.

1 investor

Volumina Medical develops advanced biomaterial technologies for soft-tissue regeneration and restoration. The company translates scientific discoveries from material science and engineering into minimally invasive medical solutions for clinical use.

1 investor

VONJO is a prescription JAK inhibitor medication used to treat patients with certain blood cancers, specifically myelofibrosis. The site presents safety and prescribing information for the drug, intended for patients and their healthcare providers.

1 investor

Voro Therapeutics develops tumor-activated biologics, specifically an antibody-based platform called PrimeBody™, designed to treat cancers including colorectal, gastric, prostate, and lung cancers while minimizing systemic toxicity. The company leverages masking technology and conditionally activated linkers to enable systemic delivery with tumor-specific activation.

1 investor

Voyage Biomedical develops medical device technology that uses cooling to prevent brain damage during stroke. The company was acquired by Penumbra (NYSE:PEN).

1 investor

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease. Many of its programs come from its TRACER AAV capsid discovery platform, which targets delivery across the blood-brain barrier.

1 investor